GLP CRO Partnering NorthEast BioLab offers GLP and GCLP compliant bioanalytical services with FDA-audited facilities, making them a strong partner for sponsors needing compliant preclinical and early clinical assays across ELISA, MS-based methods, and cell/gene therapy platforms.

Diverse Platforms Capabilities span immunoassays (ELISA, MSD, Luminex, Western) to LC-MS/MS and cell/gene therapy assays (flow cytometry, qPCR/dPCR), enabling end-to-end outsourcing for pharmacokinetics, toxicokinetics, immunogenicity, biomarker profiling, and mech‑of‑action studies.

Compact Scale Advantage With 11-50 employees and competitive pricing, NorthEast BioLab targets agile, mid‑sized biotech sponsors seeking high-touch, timely turnaround without the bandwidth constraints of larger CROs.

Strategic Collaboration Recent partnerships and technology transfer activities, such as the GC Labs collaboration and cytogenetics expertise, indicate potential for joint development projects and expanded service offerings for existing sponsors.

Growth Signals Revenue in the mid‑single to high‑single digit millions, ongoing platform expansion, and a focus on fast sample analysis align with sponsors pursuing rapid milestones, offering upsell opportunities in assay development, validation, and multiplex cytokine panels.